WIBA-AWARDS
26.5.2024 01:09:34 CEST | Business Wire | Press release
The sixth annual WIBA Awards for social media personalities on a mission to change the world took place on May 24th, 2024, at the iconic Hotel Martinez during the Cannes Film Festival. The event gathered hundreds of top global content creators responsible for the year’s most viral moments. The evening featured a cocktail reception, a Gala Dinner, and the Awards ceremony with a special performance by Sonique.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240525509294/en/
WIBA 2024 Winners (Photo: Business Wire)
The event awarded international celebrities and extraordinary personalities such as Coco Rocha, Lena Mahfouf (Situations), Alexandre Maras, Hyram, Sasha Ray and others. The Grand Prix WIBA title 2024 assigned to Burak Ozdemir, Turkish chef and restaurateur with over 129M followers on social media.
WIBA Awards were overseen by the World Influencers Association (WIBA) based in Monaco. It was the first and the only international award honoring the work of social media personalities across multiple categories.
WIBA Awards title holders are the top world influencers, such as Maye Musk, Richard Orlinski, Khaby Lame, Nusret Gökçe, Nikkie Tutorials, Gianluca Vacchi, Foodgod, Kat Graham, Kelly Rutherford, Ellen Von Unwerth and others.
WIBA Awards event highlighted the most followed social causes, empowered diverse influencers' voices, encouraged collaboration, and fostered a sense of a global community of peers. The typical instant reach of a WIBA Awards ballroom was over 200 million impressions.
WIBA 2024 Titles Holders 2024
Burak Özdemir: Grand Prix
Coco Rocha: Fashion Model Business Icon & Women Empowerment Advocate
Lena Situations: Motivation & Encouragement Lifestyle Influencer
Alexandre Maras: Most Influential Journalist in Social Media 2024
Hyram: Best Influential Skincare Expert
Mohamed Cheikh: French Contest Winners
Reem Khabbazeh: Most Influential Social Personality of Middle East
Lee Levi: Influential Actress in Social Media
Maxim Ivanchuk: Best Aesthetic Medicine Influencer
Esteriore Brothers: Best Entertainment Influencers
Max Mariola: Best Food Influencer
Sasha Ray: Fashion Lifestyle Influencer
Jeff Hamilton: Influential Celebrity Fashion Artist
Pietro Checchi: New Name of Italian Tiktok
Marcello D’Onofrio: Empowerment Celebrities Management Leader
Nadine Mirada: European Model Influencer
Daniel Asante: Social Media Model Influencer
Alex & Tom : Best Education Influencers
Elena Hazinah : Best Beauty Influencer
Angelina Usanova: Social Activity & Philanthropy Influencer
Francine Ehlke: Best Latin America Influencer
Youmna Khoury: Influential Beauty Business Leader
Urvashi Rautela: Influential Indian Star
PHOTOS: https://www.picdrop.com/gettyimagesit/6VAkztDsX3
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240525509294/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom